These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression. Julik E; Reyes-Del Valle J J Virol; 2016 Jun; 90(11):5270-5279. PubMed ID: 26984727 [TBL] [Abstract][Full Text] [Related]
25. Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. de Vries P; van Binnendijk RS; van der Marel P; van Wezel AL; Voorma HO; Sundquist B; Uytdehaag FG; Osterhaus AD J Gen Virol; 1988 Mar; 69 ( Pt 3)():549-59. PubMed ID: 3258355 [TBL] [Abstract][Full Text] [Related]
26. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Taylor J; Weinberg R; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E Virology; 1992 Mar; 187(1):321-8. PubMed ID: 1736535 [TBL] [Abstract][Full Text] [Related]
27. Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? Santibanez S; Niewiesk S; Heider A; Schneider-Schaulies J; Berbers GAM; Zimmermann A; Halenius A; Wolbert A; Deitemeier I; Tischer A; Hengel H J Gen Virol; 2005 Feb; 86(Pt 2):365-374. PubMed ID: 15659756 [TBL] [Abstract][Full Text] [Related]
28. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. de Swart RL; Yüksel S; Osterhaus AD J Virol; 2005 Sep; 79(17):11547-51. PubMed ID: 16103210 [TBL] [Abstract][Full Text] [Related]
29. Canine distemper virus (CDV) immune-stimulating complexes (Iscoms), but not measles virus iscoms, protect dogs against CDV infection. De Vries P; Uytdehaag FG; Osterhaus AD J Gen Virol; 1988 Aug; 69 ( Pt 8)():2071-83. PubMed ID: 3404123 [TBL] [Abstract][Full Text] [Related]
30. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Weidinger G; Ohlmann M; Schlereth B; Sutter G; Niewiesk S Vaccine; 2001 Apr; 19(20-22):2764-8. PubMed ID: 11282186 [TBL] [Abstract][Full Text] [Related]
31. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Green TD; Newton BR; Rota PA; Xu Y; Robinson HL; Ross TM Vaccine; 2001 Oct; 20(1-2):242-8. PubMed ID: 11567770 [TBL] [Abstract][Full Text] [Related]
32. Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. Varsanyi TM; Morein B; Löve A; Norrby E J Virol; 1987 Dec; 61(12):3896-901. PubMed ID: 2960833 [TBL] [Abstract][Full Text] [Related]
33. Measles virus-specific CD4 T-cell activity does not correlate with protection against lung infection or viral clearance. Pueschel K; Tietz A; Carsillo M; Steward M; Niewiesk S J Virol; 2007 Aug; 81(16):8571-8. PubMed ID: 17553890 [TBL] [Abstract][Full Text] [Related]
34. Protective effects of a DNA vaccine expressing the infectious salmon anemia virus hemagglutinin-esterase in Atlantic salmon. Mikalsen AB; Sindre H; Torgersen J; Rimstad E Vaccine; 2005 Sep; 23(41):4895-905. PubMed ID: 16005119 [TBL] [Abstract][Full Text] [Related]
35. Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface. Klagge IM; ter Meulen V; Schneider-Schaulies S Eur J Immunol; 2000 Oct; 30(10):2741-50. PubMed ID: 11069053 [TBL] [Abstract][Full Text] [Related]
36. Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. Fournier P; Brons NH; Berbers GA; Wiesmüller KH; Fleckenstein BT; Schneider F; Jung G; Muller CP J Gen Virol; 1997 Jun; 78 ( Pt 6)():1295-302. PubMed ID: 9191921 [TBL] [Abstract][Full Text] [Related]
37. Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies. El Kasmi KC; Fillon S; Theisen DM; Hartter H; Brons NH; Muller CP J Gen Virol; 2000 Mar; 81(Pt 3):729-35. PubMed ID: 10675410 [TBL] [Abstract][Full Text] [Related]
38. Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins. Polack FP; Lydy SL; Lee SH; Rota PA; Bellini WJ; Adams RJ; Robinson HL; Griffin DE Clin Vaccine Immunol; 2013 Feb; 20(2):205-10. PubMed ID: 23239799 [TBL] [Abstract][Full Text] [Related]
39. Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. de Swart RL; Vos HW; UytdeHaag FG; Osterhaus AD; van Binnendijk RS J Virol Methods; 1998 Mar; 71(1):35-44. PubMed ID: 9628219 [TBL] [Abstract][Full Text] [Related]
40. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. Wild TF; Malvoisin E; Buckland R J Gen Virol; 1991 Feb; 72 ( Pt 2)():439-42. PubMed ID: 1993882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]